Transgene Biotek Limited has clarified that it is not required to submit a Statement of Deviation or Variation for fund utilization.

This is because the company did not raise capital through public, rights, or preferential issues during the recent quarter.

Essentially, there were no new shares issued via these specific avenues, meaning there are no proceeds to report on how they were used.

This update provides clarity to shareholders regarding the company's capital-raising activities for the period.